Data-driven care
Outcomes Matter: Effectiveness and Efficiency
At Wholeview, our goal is long-term treatment success. We meet or exceed industry averages for nearly all commonly tracked industry metrics.
Why does data matter? It shows that our patients find it easy to engage – and that we help them stay committed.
Access to treatment
- Wholeview prioritizes quick access to care, with an average of five days between the patient’s first contact and the intake evaluation
- 82% of patients who undergo an intake evaluation engage in treatment. A full 100% of Intensive Outpatient Program (IOP) patients continue with outpatient treatment after completing the program
Initiation and engagement rate
- 72% of Wholeview patients get started with their treatment program within two weeks of their diagnosis
- 100% of Wholeview patients engage in two or more services within 34 days of their initiation visit
- Patients interact with Wholeview on an average of 19 visits in their first month of care
Evidence-based psychiatric support
- 73% of Wholeview patients who were diagnosed with alcohol use disorder (AUD) were prescribed medications for their AUD. Note that nationally only 2% of patients with AUD received medication
- 88% of Wholeview patients who were diagnosed with Opioid use disorder were prescribed medications for their OUD. Note that nationally only 20% of patients with OUD receive medication nationally.
Reduction in severe and moderate depression and anxiety
- The percentage of patients with severe and moderate depression decreased significantly over time, with all patients reaching normal or mild levels by the eighth month of therapy
- The percentage of patients with severe and moderate anxiety levels decreased, with all patients achieving normal or mild levels by the eighth month of therapy
Reduction in addiction severity
Wholeview patients demonstrate a significant reduction in the risk of relapse, dropping from 20% in month one of therapy to 0% in month eight of therapy
Satisfaction
- On Wholeview’s most recent satisfaction survey, 88% of patients gave a 10 out of 10 score
- Overall, the net promoter score was 76 (an “excellent” rating.) This is 2.5x the industry average.